Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer

Yoshito Komatsu(Hokkaido University Hospital), Atsushi Ohtsu(National Cancer Center Hospital East)
Investigational New Drugs
December 14, 2013
Cited by 30


Related Papers

No related papers found

Powered by citation graph analysis